CompletedPhase 3

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

United States630 participantsStarted 2007-07

Plain-language summary

The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection. * Adequate renal, hepatic and bone marrow function. * Performance status 0 or 1. Exclusion Criteria: * Prior treatment with any systemic chemotherapy for metastatic disease. * Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors. * Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent. * Inability to take oral medication.

What they're measuring

Overall Survival (OS)

Timeframe: Baseline until death or at least 1 year after the randomization of last participant

Trial details

NCT IDNCT00471146

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-01

Results submitted2012-02-25

View on ClinicalTrials.gov More Carcinoma, Pancreatic Ductal trials